These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1498451)

  • 1. Low-intensity combination chemotherapy maximizes host survival time for tumors containing drug-resistant cells.
    Martin RB; Fisher ME; Minchin RF; Teo KL
    Math Biosci; 1992 Jul; 110(2):221-52. PubMed ID: 1498451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal control of tumor size used to maximize survival time when cells are resistant to chemotherapy.
    Martin RB; Fisher ME; Minchin RF; Teo KL
    Math Biosci; 1992 Jul; 110(2):201-19. PubMed ID: 1498450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of alternating chemotherapy with 2 non-cross-resistant drug combinations on human alimentary and breast cancer xenografts in nude mice].
    Fujita F; Fujita M; Yamauchi T; Sakamoto Y; Shimozuma K; Inaba H; Taguchi T
    Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 1):1297-304. PubMed ID: 2953311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-dimensional chemotherapy simulations demonstrate fundamental transport and tumor response limitations involving nanoparticles.
    Sinek J; Frieboes H; Zheng X; Cristini V
    Biomed Microdevices; 2004 Dec; 6(4):297-309. PubMed ID: 15548877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What does not kill a tumour may make it stronger: In silico insights into chemotherapeutic drug resistance.
    Hamis S; Nithiarasu P; Powathil GG
    J Theor Biol; 2018 Oct; 454():253-267. PubMed ID: 29909142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapeutic Dose Scheduling Based on Tumor Growth Rates Provides a Case for Low-Dose Metronomic High-Entropy Therapies.
    West J; Newton PK
    Cancer Res; 2017 Dec; 77(23):6717-6728. PubMed ID: 28986381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal Therapy Scheduling Based on a Pair of Collaterally Sensitive Drugs.
    Yoon N; Vander Velde R; Marusyk A; Scott JG
    Bull Math Biol; 2018 Jul; 80(7):1776-1809. PubMed ID: 29736596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy burden, drug resistance, and optimal treatment regimen for cancer chemotherapy.
    Boldrini JL; Costa MI
    IMA J Math Appl Med Biol; 2000 Mar; 17(1):33-51. PubMed ID: 10757031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal drug regimens in cancer chemotherapy: a multi-objective approach.
    Batmani Y; Khaloozadeh H
    Comput Biol Med; 2013 Dec; 43(12):2089-95. PubMed ID: 24290925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms to improve chemotherapy effectiveness.
    Young RC
    Cancer; 1990 Feb; 65(3 Suppl):815-22. PubMed ID: 2406004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer chemotherapy.
    Secchi GC
    Ann Ital Med Int; 1990; 5(3 Pt 3):288-95. PubMed ID: 2081089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
    Leggas M; Stewart CF; Woo MH; Fouladi M; Cheshire PJ; Peterson JK; Friedman HS; Billups C; Houghton PJ
    Clin Cancer Res; 2002 Sep; 8(9):3000-7. PubMed ID: 12231547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A qualitative approach to cell growth modeling and simulation for cancer chemotherapy.
    Gaglio S; Giacomini M; Nicolini C; Ruggiero C
    IEEE Trans Biomed Eng; 1991 Apr; 38(4):386-9. PubMed ID: 1855803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelling chemotherapy resistance in palliation and failed cure.
    Monro HC; Gaffney EA
    J Theor Biol; 2009 Mar; 257(2):292-302. PubMed ID: 19135065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of tumours on normal cells and optimal chemotherapy regimens: the case of several drugs and toxicity constraints.
    Matveev AS; Savkin AV
    Math Med Biol; 2005 Jun; 22(2):143-62. PubMed ID: 15781427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Alternating non-cross resistant multi-drug chemotherapy against malignant lymphoma (CAMBO-VIP)--consideration of the dose intensity].
    Hirano M; Okamoto M; Maruyama F; Shinkai K; Miyazaki H; Ezaki K
    Gan To Kagaku Ryoho; 1990 Oct; 17(10):1982-8. PubMed ID: 2221923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.